Direct comparison between regional cerebral metabolism in progressive supranuclear palsy and Parkinson's disease

Movement Disorders

Volumn 20, Issue 8, 2005, Pages 1021-1030

  Klein, Reinoud C ^a   de Jong, Bauke M ^a   de Vries, Joeke J ^a   Leenders, Klaus L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cingulate gyrus; FDG; Hallucination; Medial frontal metabolism; Parkinson's disease; PET; Progressive supranuclear palsy; SPM

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FRONTAL LOBE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HALLUCINATION; HUMAN; MALE; MESENCEPHALON; MOTOR CORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PARIETAL LOBE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE; VISUAL CORTEX;

AGED; BLOOD GLUCOSE; BRAIN MAPPING; CEREBRAL CORTEX; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 26444432393     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20493     Document Type: Article

References (46)

1. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
2. Litvan I. Progressive supranuclear palsy revisited. Acta Neurol Scand 1998;98:73-84.
3. Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001;58:1076-1079.
4. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988;24: 399-406.
5. Garraux G, Salmon E, Degueldre C. Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia. Neuroimage 1999; 10:149-162.
6. Goffinet AM, De Volder AG, Gillain C, et al. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol 1989;25:131-139.
7. Hosaka K, Ishii K, Sakamoto S, et al. Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration. J Neurol Sci 2002;199:67-71.
8. Karbe H, Grond M, Huber M, Herholz K, Kessler J, Heiss WD. Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. J Neurol 1992;239:98-102.
9. Salmon E, Van der Linden MV, Franck G. Anterior cingulate and motor network metabolic impairment in progressive supranuclear palsy. Neuroimage 1997;5:173-178.
10. Leenders KL, Frackowiak RSJ, Lees AJ. Steele-Richardson-Olszewski syndrome, brain energy metabolism, blood flow and fluorodopa uptake measured by PET. Brain 1988;111:615-630.
11. Nagahama Y, Fukuyama H, Turjanski N, et al. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord 1997;12:691-696.
12. Blin J, Baron JC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990;47:747-752.
13. Foster NL, Minoshima S, Johanns J, et al. PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 2000;54:1768-1773.
14. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
15. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 2001; 16:1014-1022.
16. Hu MT, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000;123(Pt 2):340-352.
17. Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 2004;51:223-233.
18. Bergstrom M, Bohm C, Ericson K, Eriksson L, Liton J. Corrections for attenuation, scattered radiation and random coincidences in a ring detector positron emission transaxial tomograph. IEEE Trans Nucl Sci 1980;27:549-554.
19. Friston KJ, Ashburner J, Poline JB, Frackowiak RSJ. Spatial realignment and normalization of images. Hum Brain Map 1995; 2:165-189.
20. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Map 1995;2:189-210.
21. Watson JD, Myers R, Frackowiak RS, et al. Area V5 of the human brain: evidence from a combined study using positron emission tomography and magnetic resonance imaging. Cereb Cortex 1993; 3:79-94.
22. de Jong BM, van Weerden TW, Haaxma R. Opsoclonus-induced occipital deactivation with a region-specific distribution. Vision Res 2001;41:1209-1214.
23. Wenzel R, Bartenstein P, Dieterich M, et al. Deactivation of human visual cortex during involuntary ocular oscillations. A PET activation study. Brain 1996;119(Pt 1):101-110.
24. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16:338-346.
25. Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain 1995;118(Pt 1):279-306.
26. Penfield W, Jasper H. Epilepsy and the functional anatomy of the human brain. Boston: Little, Brown; 1954.
27. Kuypers HGJM. Anatomy of the descending pathways. The nervous system II. Vol. 2. Motor control. Part 1. Bethesda, MD: American Physiological Society; 1981. p 597-666.
28. Picard N, Strick PL. Motor areas of the medial wall: a review of their location and functional activation. Cereb Cortex 1996;6:342-353.
29. Braak H. A primitive gigantopyramidal field buried in the depth of the cingulate sulcus of the human brain. Brain Res 1976;109:219-223.
30. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol 2002;1:359-369.
31. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019.
32. Hauw JJ, Verny M, Delaere P, Cervera P, He Y, Duyckaerts C. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett 1990;119:182-186.
33. D'Antona R, Baron JC, Samson Y, et al. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985;108(Pt 3):785-799.
34. Jellinger K, Riederer P, Tomonaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl 1980;16:111-128.
35. Goodale MA, Milner AD. Separate visual pathways for perception and action. Trends Neurosci 1992;15:20-25.
36. Danta G, Hilton RC. Judgment of the visual vertical and horizontal in patients with Parkinsonism. Neurology 1975;25:43-47.
37. de Jong BM, Frackowiak RS, Willemsen AT, Paans AM. The distribution of cerebral activity related to visuomotor coordination indicating perceptual and executional specialization. Brain Res Cogn Brain Res 1999;8:45-59.
38. Hovestadt A, de Jong GJ, Meerwaldt JD. Spatial disorientation as an early symptom of Parkinson's disease. Neurology 1987;37:485-487.
39. Richards M, Cote LJ, Stern Y. The relationship between visuospatial ability and perceptual motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:400-406.
40. Waterfall ML, Crowe SF. Meta-analytic comparison of the components of visual cognition in Parkinson's disease. J Clin Exp Neuropsychol 1995;17:759-772.
41. Korczyn AD. Hallucinations in Parkinson's disease. Lancet 2001; 358:1031-1032.
42. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:42-49.
43. Silbersweig DA, Stern E, Frith C, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995;378:119-176.
44. Leenders KL, Wolfson L, Gibbs JM, et al. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain 1985;108:171-191.
45. Rougemont D, Baron JC, Collard P, Bustany P, Comar Comar D, Agid Y. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1984;47:824-830.
46. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001;57: 2083-2088.